Abstract
Purpose/Objective: Previous randomized trials have shown a benefit with concurrent use of the hypoxic cell cytotoxin MitomycinC (MC) and radiation (RT) in the management of SCCHN. Based on laboratory data demonstrating superior hypoxic cell cytotoxicity with Porfiromycin (PO, Methyl-mitomycinC), and a Phase I trial demonstrating acceptable toxicity with concurrent RT and PO at 40mg/M2, we conducted a randomized trial comparing MC to PO in combination with RT in the management of SCCHN.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
